natgillin/translations-raw huggingface dataset:
• previously had nausea, vomiting and diarrhoea during cancer treatment 
• če so se pri vas med zdravljenjem raka že pojavili siljenje na bruhanje, bruhanje in driska.
Uncommon: Status epilepticus, coma, cerebrovascular accident, peripheral sensorimotor neuropathy, lethargy, hypotonia, neurotoxicity, polyneuropathy, polyneuropathy in malignant disease, burning sensation, somnolence, cognitive disorder, facial palsy, encephalopathy, hydrocephalus 
epileptični status, koma, cerebrovaskularni inzult, periferna senzomotorična nevropatija, letargija, hipotonija, nevrotoksičnost, polinevropatija, polinevropatija pri maligni bolezni, pekoč občutek,
• feeling hot 
• občutek vročine;
Uncommon: Haemarthrosis, musculoskeletal discomfort, sensation of heaviness 
hemartroza, kostno-mišično nelagodje, občutek obteženosti
The infusion site reactions observed include pain, phlebitis, discolouration, redness, oedema and rash. 
Opažene reakcije na mestu infundiranja vključujejo bolečino, flebitis, spremembo barve, rdečino, edem in izpuščaje.
Withhold treatment until recovery 
Odložite zdravljenje do izboljšanja stanja
After reconstitution, each mL of solution contains 1 mg of paclitaxel (micellar). 
Po rekonstituciji en ml raztopine vsebuje 1 mg (micelarnega) paklitaksela.
How to store Apealea 
Shranjevanje zdravila Apealea
Uncommon: Angioedema, rash generalised, skin discolouration, hyperhidrosis, rash papular, dermatitis bullous, swelling face, pigmentation disorder, dry skin, cold sweat, livedo reticularis, nail disorder, pruritus allergic, skin disorder 
angioedem, generaliziran izpuščaj, sprememba barve kože, hiperhidroza, papulozni izpuščaj, bulozni dermatitis, otekanje obraza, motnja pigmentacije, suha koža, hladen pot, retikularni livedo, bolezen nohtov, alergijski pruritus, bolezni kože
Excipients: N-(all-trans-retinoyl)-L-cysteic acid methyl ester sodium salt, N-(13-cis-retinoyl)-L-cysteic acid methyl ester sodium salt, sodium hydroxide. 
Pomožne snovi: natrijeva sol metilnega estra N-(all-trans retinol)-L-cisteinske kisline, natrijeva sol metilnega estra N-(13-cis retinol)-L-cisteinske kisline, natrijev hidroksid.
Back pain, bone pain, musculoskeletal pain, muscular weakness, pain in extremity 
bolečina v hrbtu, bolečina v kosteh, kostno-mišična bolečina, oslabelost mišic, bolečine v udih
Paclitaxel is excreted in human milk. 
Paklitaksel se izloča v materino mleko.
One vial contains 60 mg of paclitaxel. 
Ena viala vsebuje 60 mg paklitaksela.
Thereby, non-inferiority was shown in the ITT population for PFS, but not for OS. At the time of analysis of the OS data, death had occurred in 56% of the patients in the group treated with paclitaxel micellar compared to 60% in the group treated with solvent-based paclitaxel (ITT population). 
V času analize podatkov o celokupnem preživetju je bilo med bolnicami v skupini, ki je bila zdravljena z micelarnim paklitakselom, 56 % smrtnih primerov, v skupini, zdravljeni s paklitakselom na osnovi topila, pa je bilo teh primerov 60 % (populacija ITT).
Uncommon: Vertigo, deafness, inner ear disorder, tinnitus 
vrtoglavica, gluhost, bolezen notranjega ušesa, tinitus
• severe nausea, vomiting or diarrhoea 
• močno siljenje na bruhanje, bruhanje ali driska;
Dose reduction: 
Zmanjšanje odmerka:
Uncommon: Circulatory collapse, venous thrombosis, vasculitis, thrombosis, hypertension, deep vein thrombosis, lymphoedema, phlebitis superficial, thrombophlebitis, blood pressure fluctuation, haemorrhage, angiopathy, hot flush, pallor 
kolaps krvnega obtoka, venska tromboza, vaskulitis, tromboza, hipertenzija, globoka venska tromboza, limfedem, površinski flebitis, tromboflebitis, nihanje krvnega tlaka, krvavitve, angiopatija, vročinski oblivi, bledica
• depression, sleeplessness, anxiety 
• depresija, nespečnost, tesnoba;
Relapse n Events 
Recidiv n Dogodki
Administering paclitaxel concomitantly with medicines known to induce either CYP2C8 or CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine) is not recommended because efficacy may be compromised because of lower paclitaxel exposures. 
rifampicin, karbamazepin, fenitoin, efavirenz in nevirapin), ni priporočljivo, saj se lahko zaradi manjše izpostavljenosti paklitakselu zmanjša učinkovitost.
Uncommon: Depression, insomnia, anxiety Nervous system disorders Very common: Peripheral sensory neuropathya,b, neuropathy peripherala,b 
Zelo pogosti: periferna senzorična nevropatijaa,b, periferna nevropatijaa,b
Apealea 60 mg powder for solution for infusion. 
Apealea 60 mg prašek za raztopino za infundiranje.
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO
Uncommon: Death, multi-organ failure, oedema, administration site pain, catheter site haemorrhage, catheter site oedema, local swelling, generalised oedema, hernia, chest pain, influenza like illness, localised oedema, hypothermia, chills, feeling hot 
smrt, odpoved več organov, edem, bolečina na mestu aplikacije, krvavitve okoli katetra, edem okoli katetra, lokalno otekanje, generaliziran edem, hernija, bolečina v prsnem košu, gripi podobna bolezen, lokaliziran edem, hipotermija, mrzlica,
• cough 
• kašelj;
Forest plot for PFS by relapse (PP population) 
Drevesni diagram za PFS glede na recidiv (populacija PP)
Abdominal pain, constipation, abdominal pain upper, flatulence, dry mouth, stomatitis 
bolečine v trebuhu, zaprtje, bolečina v zgornjem delu trebuha, napenjanje, suha usta, stomatitis
Package leaflet: Information for the user Apealea 60 mg powder for solution for infusion paclitaxel 
Navodilo za uporabo: Apealea 60 mg prašek za raztopino za infundiranje paklitaksel
• lung inflammation, influenza, tonsil inflammation 
• vnetje pljuč, gripa, vnetje mandljev;
Uncommon: Metastatic pain 
bolečina zaradi metastaz
• reactions at the infusion site such as pain, inflammation, discolouration, redness, swelling, 
• reakcije na mestu infundiranja, kot so bolečina, vnetje, sprememba barve, rdečica, oteklina, mravljinčenje, izpuščaji, krvavitev;
Apealea 60 mg powder for solution for infusion paclitaxel 
Apealea 60 mg prašek za raztopino za infundiranje paklitaksel
The model indicated that a 0.2 m2 increase in BSA would lead to a 9% increase in the elimination rate. 
Iz modela je razvidno, da povečanje telesne površine za 0,2 m2 pomeni
Neutropenia as a serious adverse reaction occurred in 29% of the patients and febrile neutropenia occurred in 3% of the patients. 
Nevtropenija kot resen neželeni dogodek se je pojavila pri 29 %
Patients with mild hepatic impairment (total bilirubin > 1 to ≤ 1.5 × upper limit of normal (ULN) and aspartate aminotransferase (AST) ≤ 10 × ULN) may be treated with the same doses as patients with normal hepatic function. 
in aspartat-aminotransferaze [AST] ≤ 10 × ULN) se lahko zdravijo z enakimi odmerki kot bolnice z normalnim delovanjem jeter.
• skin infections, including infections at the infusion site 
• okužba sečil, vnetje sečnega mehurja; • okužbe kože, vključno z okužbami na mestu infundiranja;
Uncommon: Hyponatraemia, hypokalaemia, hypomagnesaemia, 
hiponatriemija, hipokaliemija, hipomagneziemija, dehidracija, zmanjšan tek
Each carton contains 1 glass vial with powder equivalent to 60 mg of paclitaxel. 
Ena škatla vsebuje eno stekleno vialo s praškom, ki ustreza 60 mg paklitaksela.
If it contacts mucous membranes, the membranes should be flushed thoroughly with water. 
Če pride v stik s sluznico, jo temeljito sperite z vodo.
• hair loss 
• izguba teka;
• abdominal pain, constipation, wind 
• bolečine v trebuhu, zaprtje, vetrovi;
− hot flushes 
− vročinski oblivi;
One vial of powder contains 60 mg paclitaxel. 
Ena viala s praškom vsebuje 60 mg paklitaksela.
• skin discolouration, pigmentation disorder 
• sprememba barve kože, motnje pigmentacije; • vnetje kože z mehurji;
Single-use vial 
viala za enkratno uporabo
Heart failure has been observed in some patients receiving Apealea. 
Pri nekaterih bolnicah, ki so prejemale zdravilo Apealea, so opazili popuščanje srca.
Reconstitution of the medicinal product 
Rekonstitucija zdravila
Haematological toxicityb neutrophil count < 1.5 × 109/L or platelet count < 100 × 109/L or febrile neutropenia 
Število nevtrofilcev < 1,5 × 109/l ali število krvnih ploščic
a Includes the following preferred terms: infusion site phlebitis, infusion site pain, injection site reaction, injection site inflammation, infusion site erythema, injection site extravasation, infusion site reaction, injection site oedema. 
reakcija na mestu injiciranja, vnetje na mestu injiciranja, eritem na mestu infundiranja, ekstravazacija na mestu injiciranja, reakcija na mestu infundiranja in edem na mestu injiciranja.
N-(all-trans-retinoyl)-L-cysteic acid methyl ester sodium salt N-(13-cis-retinoyl)-L-cysteic acid methyl ester sodium salt Sodium hydroxide (for pH adjustment) 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi natrijeva sol metilnega estra N-(all-trans retinol)-L-cisteinske kisline natrijeva sol metilnega estra N-(13-cis retinol)-L-cisteinske kisline natrijev hidroksid (za prilagoditev pH)
Apealea has been given as monotherapy in a total of 132 patients at doses ranging between 90 mg/m2 in a 3-week regimen to weekly doses of 250 mg/m2 for various indications. 
90 mg/m2 vsake tri tedne in 250 mg/m2 v tedenskih odmerkih pri različnih indikacijah.
• dry mouth, inflammation of the inner lining of the mouth 
• suha usta, vnetje ustne sluznice;
• severe reactions at the site of infusion 
• hude reakcije na mestu infundiranja; • alergijska reakcija;
• joint or muscle pain or discomfort 
• bolečine ali nelagodje v sklepih ali mišicah;
• abnormal sensation such as tingling, burning, pricking or numbness of the skin or in the mouth 
• zmanjšana občutljivost za dotik ali bolečino; • nenormalni občutki, kot so mravljinčenje, pekoč občutek, zbadanje ali omrtvelost, ki se pojavijo na koži ali v ustih;
• diarrhoea, nausea, vomiting 
• driska, siljenje na bruhanje, bruhanje;
Gastrointestinal adverse reactions are very common. 
Neželeni učinki na prebavila so zelo pogosti.
• low level of blood platelets or red blood cells 
• nizka raven belih krvničk, imenovanih levkociti in granulociti; • nizka raven krvnih ploščic ali rdečih krvničk;
Neuropathy 
Nevropatija
Common (may affect up to 1 in 10 people): 
pogosti (pojavijo se lahko pri največ 1 od 10 bolnic):
General disorders and administration site conditions Asthenia and fatigue were very common and occurred in 23% and 11% of patients, respectively. 
Zelo pogosti sta bili astenija (pri 23 % bolnic) in utrujenost (pri 11 % bolnic).
• chest pain or discomfort 
• bolečine ali nelagodje v prsnem košu;
For patients with moderate to severe impairment (total bilirubin > 1.5 to ≤ 5 × ULN and AST ≤ 10 × ULN), a 20% reduction in dose is recommended. 
Pri bolnicah z zmerno do hudo okvaro (skupna količina bilirubina > 1,5 do ≤ 5 × ULN in
• have a count of white blood cells called neutrophils below 1.5 × 109/L before start of the therapy 
• če imate pred začetkom zdravljenja število belih krvničk, imenovanih nevtrofilci, nižje od
When reconstituted, this medicinal product contains up to approximately 1.6 g sodium per dose (0.9 g/m2 BSA; 3.6 mg per mL), equivalent to 80% of the WHO recommended maximum daily intake of 2 g sodium for an adult. 
3,6 mg/ml), kar je enako 80 % največjega dnevnega vnosa za odrasle osebe, ki ga priporoča SZO in znaša 2 g.
• Common (may affect up to 1 in 10 people): 
• zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnic):
• numbness, tingling, pricking sensation, sensitivity to touch or muscle weakness You may need additional medicines if you develop any of these symptoms. 
• omrtvelost, mravljinčenje, zbadanje, občutljivost na dotik ali oslabelost mišic.
Shelf life after reconstitution 
Rok uporabe po rekonstituciji
• cancer of the fallopian tubes (the connection between the ovaries and the womb) It is used when other therapies have not worked. 
• rak jajcevodov (povezave med jajčniki in maternico).
• blurred vision, eye discomfort or irritation, watery eyes 
• zamegljen vid, neprijeten občutek v očeh ali draženje oči, solzne oči;
However, a population pharmacokinetics study of 168 patients (86 males and 82 females) treated with solvent-based paclitaxel has been reported. 
Vpliv starosti, spola, rase in telesne velikosti Analize vpliva starosti, spola ali telesne velikosti na izločanje zdravila Apealea niso izvedli, so pa poročali o farmakokinetični študiji pri skupini 168 bolnikov (86 moških in 82 žensk), ki so jih zdravili s paklitakselom na osnovi topila.
Hypersensitivity 
hiperemija
d Includes the following preferred terms: infusion site pain, infusion site phlebitis, infusion site reaction, infusion site discolouration, infusion site erythema, infusion site extravasation, infusion site inflammation, infusion site oedema, infusion site paraesthesia, infusion site irritation, and infusion site rash. 
reakcija na mestu infundiranja, sprememba barve kože na mestu infundiranja, eritem na mestu infundiranja, ekstravazacija na mestu infundiranja, vnetje na mestu infundiranja, edem na mestu infundiranja, parestezija na mestu infundiranja, draženje na mestu infundiranja in izpuščaji na mestu infundiranja.
Apealea is a cancer medicine containing the active substance paclitaxel, which belongs to a group of medicines called taxanes. 
Apealea je zdravilo proti raku z učinkovino paklitaksel.
Hypotension, flushing, phlebitis, vein pain, hyperaemia 
hipotenzija, rdečica, flebitis, bolečine v venah,
The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and CYP3A4 (see section 5.2). 
Dajanje paklitaksela skupaj z zdravili, za katera je znano, da inducirajo CYP2C8 ali CYP3A4 (npr.
Forest plot for OS by relapse (PP population) 
Drevesni diagram za OS glede na recidiv (populacija PP)
Uncommon: Vaginal haemorrhage, pelvic pain, breast pain 
vaginalne krvavitve, medenična bolečina, bolečina v dojkah
Posology 
Ugotoviteva
Tell your doctor or nurse immediately if you have any of the following: • Very common (may affect more than 1 in 10 people): 
• otekanje gležnjev, stopal, obraza ali prstov; občasni (pojavijo se lahko pri največ 1 od 100 bolnic):
Paclitaxel (solvent-based) 
Paklitaksel (na osnovi topila)
Not known: 
Občasni:
− N-(all-trans-retinoyl)-L-cysteic acid methyl ester sodium salt 
− natrijeva sol metilnega estra N-(all-trans retinol)-L-cisteinske kisline
Dose recommendations for Apealea as well as for carboplatin in the case of myelosuppression should be followed (see section 
Pri mielosupresiji je treba upoštevati priporočila glede odmerkov zdravila Apealea in karboplatina (glejte poglavje 4.2).
Almost all patients experienced anaemia, decreased platelet count and decreased white blood cell count of any grade during the treatment period (98%, 93% and 98%, respectively). 
zmanjšano število krvnih ploščic oziroma zmanjšano število belih krvnih celic katere koli stopnje (pri
Hypersensitivity Uncommon: Anaphylactic shock, drug hypersensitivity 
anafilaktični šok, preobčutljivost za zdravilo
• mouth and throat pain or discomfort, throat disorder, bleeding gums 
• bolečine ali nelagoden občutek v ustih in grlu, bolezen grla, krvavitev iz dlesni; • vnetje želodčne sluznice, nelagodje ali napihnjenost v trebuhu, bolečine v spodnjem delu trebuha;
− blood vessel inflammation 
− vnetje krvnih žil;
Administration precautions 
Previdnostni ukrepi pri dajanju zdravila
Nervous system disorders 
ali motorična nevropatija stopnje
infection 
ZDRAVILA
− N-(13-cis-retinoyl)-L-cysteic acid methyl ester sodium salt 
− natrijeva sol metilnega estra N-(13-cis retinol)-L-cisteinske kisline
• breathing difficulties, nasal congestion 
• odpoved pljuč, zožitev dihalnih poti;
Uncommon: Respiratory failure, epistaxis, cough, rhinorrhoea, oropharyngeal pain, pharyngeal disorder, asphyxia, bronchospasm, dysphonia, rhinitis allergic, allergic cough, oropharyngeal discomfort Gastrointestinal disorders Very common: Diarrhoeaa, nauseaa, vomitinga 
asfiksija, bronhospazem, disfonija, alergijski rinitis, alergijski kašelj, orofaringealno nelagodje
Gastrointestinal disorders 
diseminirana intravaskularna koagulacijaa,
Dyspnoea, nasal congestion 
hematohezija, parestezija ust
Only reconstitute Apealea using one of the following commercially available solutions for reconstitution: - sodium chloride 9 mg/mL (0.9%) solution suitable for infusion; - lactated Ringer's solution suitable for infusion; - acetated Ringer's solution suitable for infusion. 
• natrijev klorid 9 mg/ml (0,9 %) raztopina, primerna za infundiranje;
• inflammation of the stomach lining, abdominal discomfort or bloating, lower abdominal pain 
bolečina v spodnjem delu trebuha, dispepsija, trdo blato, motnja delovanja črevesja, krvavitev dlesni,
Antihistamines 
Žilne bolezni
− puffing of the face 
− zabuhel obraz.
This is similar to that seen in most of the earlier studies. 
To je podobno kot v večini predhodnih študij.
The uptake of water should be monitored frequently. 
Vnos vode je treba pogosto spremljati.
No other source of drinking water should be available. 
Noben drug vir pitne vode ne sme biti na voljo.
Chickens were authorised as a target species in Belgium, France, Hungary and Poland. 
Piščanci Piščanci so bili dovoljeni kot ciljna živalska vrsta v Belgiji, Franciji, na Madžarskem in Poljskem.
However, also see text under section 4.4. 
Glejte tudi poglavje 4.4.
The possible risk for the environment has not been considered as part of this referral. 
Morebitno tveganje za okolje ni bilo obravnavano kot del tega napotitvenega postopka.
There is no specific antidote, treatment is symptomatic. 
Specifičnega antidota ni, zdravljenje je simptomatsko.
Hungary Zoetis Hungary Kft. Budapest, Alkotás u. 
Madžarska Zoetis Hungary Kft. Budapest, Alkotás u.
• The restriction of the indications to those that are adequately substantiated by efficacy data; 
• omejitve indikacij na tiste, ki so ustrezno utemeljene s podatki o učinkovitosti;
The main areas of disharmony in the existing product information relate to: 
Glavna področja neskladja v obstoječih informacijah o zdravilu se nanašajo na:
ATC Vet Code: QJ01FF02 
Oznaka ATC vet: QJ01FF02
This evaluation focuses on issues in regards to the harmonisation that may change the benefit-risk balance. 
To vrednotenje se osredotoča na vprašanja v zvezi z usklajevanjem, ki lahko spremenijo razmerje med koristmi in tveganjem.
Human and animal bacteria share the same resistance determinants. 
Bakterije človeka in živali imajo enake determinante odpornosti.
The description and validation of the GC/MS analytical method was considered acceptable. 
Opis in validacija analitične metode GC/MS sta se štela za sprejemljivo.
The daily amount is to be added to the drinking water in such a way that all medication will be consumed within 24 hours. 
Dnevno količino dodamo v pitno vodo tako, da bo vso zdravilo porabljeno v 24 urah.
Care should be taken not to raise and inhale any dust. 
Treba je paziti, da se ne dviguje in vdihava prahu.
The medicated water should be the only source of drinking water for the animals for the entire duration of the treatment period. 
Medicirana voda mora biti edini vir pitne vode za živali za celotno trajanje zdravljenja.
Contact with skin and eyes should be avoided. 
Izogibajte se stiku s kožo in očmi.
As such, these data are considered to support extrapolation of the findings from the abovementioned studies conducted in the USA in the 1980s to the current EU situation. 
Podatki v tej obliki se štejejo, da podpirajo ekstrapolacijo ugotovitev iz zgoraj omenjenih študij, izvedenih v ZDA v 1980-ih, na trenutne razmere v EU.
The intake of medicated water depends on the physiological and clinical condition of the animals. 
Vnos medicirane vode je odvisen od fiziološkega in kliničnega stanja živali.
In order to obtain the correct dosage, the concentration of the lincomycin has to be adjusted accordingly. 
Da bi dobili pravilen odmerek, je treba ustrezno prilagoditi koncentracijo linkomicina.
The concentration to be used depends on the actual body weight and the water consumption of the animals and can be calculated according to the following formula: 
Koncentracija, ki jo je treba uporabiti, je odvisna od dejanske telesne mase in porabe vode živali in se lahko izračuna v skladu z naslednjo formulo:
Repeated or prolonged use should be avoided by improving the farm management and hygiene practices. 
Večkratni ali dolgotrajnejši uporabi se je treba izogniti z izboljšanjem upravljanja kmetij in higienskih dobrih praks.
The use of suitably calibrated weighing equipment is recommended if part packs are used. 
Priporoča se uporaba primerne kalibrirane opreme za tehtanje, če se uporabljajo delne količine.
Pigs were already authorised as a target species for all products concerned by this referral procedure. 
Prašiči so že bili odobreni kot ciljna živalska vrsta za vsa zdravila, na katera se nanaša ta napotitveni postopek.
In both studies significant differences were noted in mortality rates between birds treated with lincomycin (0% and 0.7%, respectively) and negative controls (14% and 7.5%, respectively). 
V obeh študijah so opazili pomembne razlike v stopnji smrtnosti med pticami, zdravljenimi s linkomicinom (0 % in 0,7 %) ter negativnimi kontrolami (14 % in 7,5 %).
Average daily water intake (litre/animal) 
Povprečni dnevni vnos vode (l/žival)
The number of animals (18 castrated males and 18 females) included in the study and their weights (36.5 to 71 kg) were adequate. 
Število živali (18 kastriranih samcev in 18 samic), vključenih v študijo, in njihova telesna masa (36,5-71 kg) sta bila primerni.
Both of these studies included 1116 birds which were divided into treatment and negative control groups. 
V študijo je bilo vključenih 1116 ptic, ki so bile razdeljene v skupini za zdravljenje in negativno kontrolo.
Do not eat, drink or smoke while handling the product. 
Med ravnanjem z zdravilom ne jejte, ne pijte ali kadite.
Excipients: For the full list of excipients, see section 6.1. 
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
The referral leads to full harmonisation of the product information. 
Rezultat napotitve je popolna uskladitev informacij o zdravilu.
In case of insufficient uptake of water, pigs should be treated parenterally. 
V primeru nezadostnega vnosa vode je treba prašiče zdraviti parenteralno.
Levels were detectable for 12 to 16 hours, with peak concentrations occurring at 4 hours. 
Vrednosti so bile zaznane za 12 do 16 ur, največje koncentracije pa so se pojavile pri 4 urah.
The potential risk of resistance development, which might impact product efficacy, and overall animal and human health, is limited through: 
Tveganje za razvoj odpornosti, ki bi lahko vplivalo na učinkovitost zdravila in splošno zdravje živali in ljudi, je omejeno zaradi:
Use only according to the benefitrisk assessment by the responsible veterinarian. 
Uporabite le v skladu z oceno razmerja korist-tveganje odgovornega veterinarja.
Administration conditions: Administration under the control or direct responsibility of a veterinary surgeon. 
Uporabe pogoji: Uprava pod nadzorom ali neposredno odgovornost veterinarja.
While the lincosamides are generally considered to be bacteriostatic agents, the activity depends on the sensitivity of the organism and concentration of the antibiotic. 
Medtem ko se linkozamidi na splošno štejejo za bakteriostatične, je aktivnost odvisna od občutljivosti organizma in koncentracije antibiotika.
The bioequivalence between the soluble powder and the premix formulation was investigated in two studies, but could not be formally demonstrated. 
Biološko enakovrednost med topnim praškom in formulacijo predmešanice so proučili v dveh študijah, vendar je niso mogli formalno dokazati.
The European Commission referred the issue due to divergent national decisions having been taken by the Member States (EU/EEA) resulting in discrepancies in the product information for Lincocin and its associated names (thereafter called Lincocin). 
Evropska komisija je to vprašanje napotila zaradi različnih nacionalnih odločitev držav članic (EU/EGP), ki so privedle do razlik v informacijah o zdravilu za zdravilo Lincocin in povezana imena (v nadaljevanju imenovano Lincocin).